BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Śmiech M, Leszczyński P, Kono H, Wardell C, Taniguchi H. Emerging BRAF Mutations in Cancer Progression and Their Possible Effects on Transcriptional Networks. Genes (Basel) 2020;11:E1342. [PMID: 33198372 DOI: 10.3390/genes11111342] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
Number Citing Articles
1 Jung T, Haist M, Kuske M, Grabbe S, Bros M. Immunomodulatory Properties of BRAF and MEK Inhibitors Used for Melanoma Therapy-Paradoxical ERK Activation and Beyond. Int J Mol Sci 2021;22:9890. [PMID: 34576054 DOI: 10.3390/ijms22189890] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
2 Maloney RC, Zhang M, Jang H, Nussinov R. The mechanism of activation of monomeric B-Raf V600E. Comput Struct Biotechnol J 2021;19:3349-63. [PMID: 34188782 DOI: 10.1016/j.csbj.2021.06.007] [Reference Citation Analysis]
3 Yao K, Zhou E, Cheng C. A B‐Raf V600E gene signature for melanoma predicts prognosis and reveals sensitivity to targeted therapies. Cancer Medicine. [DOI: 10.1002/cam4.4491] [Reference Citation Analysis]
4 Lin CC, Lefferts JA, Chan AM, Zanazzi G. Rare Activating BRAF Alteration Involving the β3-αC Kinase Domain in Ganglioglioma. J Neuropathol Exp Neurol 2021:nlab013. [PMID: 33611593 DOI: 10.1093/jnen/nlab013] [Reference Citation Analysis]
5 Nascente EP, Amorim RL, Fonseca-Alves CE, de Moura VMBD. Comparative Pathobiology of Canine and Human Prostate Cancer: State of the Art and Future Directions. Cancers (Basel) 2022;14:2727. [PMID: 35681707 DOI: 10.3390/cancers14112727] [Reference Citation Analysis]
6 Zhao P, Zhuang L, Wang X, Huang S, Wu H, Zhou Y, Yan Y, Zhang F, Shen R, Li J, Liu S, Zhang R, Dong P, Mao Y, Fan Y, He C, Sun J, Zhang L, Hu Q, Wan H, Feng J, Bai C, He F, Tao W. Discovery of spiro amide SHR902275: A potent, selective, and efficacious RAF inhibitor targeting RAS mutant cancers. Eur J Med Chem 2022;228:114040. [PMID: 34906761 DOI: 10.1016/j.ejmech.2021.114040] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
7 Li N, Xu Y, Fan Y. [Current Advance in Targeted Treatment and Immunotherapy for BRAF-mutant 
Advanced Non-small Cell Lung Cancer]. Zhongguo Fei Ai Za Zhi 2021;24:714-22. [PMID: 34696543 DOI: 10.3779/j.issn.1009-3419.2021.101.29] [Reference Citation Analysis]
8 Sibuh BZ, Gupta PK, Taneja P, Khanna S, Sarkar P, Pachisia S, Khan AA, Jha NK, Dua K, Singh SK, Pandey S, Slama P, Kesari KK, Roychoudhury S. Synthesis, In Silico Study, and Anti-Cancer Activity of Thiosemicarbazone Derivatives. Biomedicines 2021;9:1375. [PMID: 34680491 DOI: 10.3390/biomedicines9101375] [Reference Citation Analysis]
9 Li H, Guo L, Cai Z. TCN1 is a potential prognostic biomarker and correlates with immune infiltrates in lung adenocarcinoma. World J Surg Onc 2022;20. [DOI: 10.1186/s12957-022-02556-8] [Reference Citation Analysis]